Loading...
•
Dec 31, 2019
Abbott Q4 2019 Earnings Report
Announced strong Q4 2019 results and provided a strong forecast for 2020.
Key Takeaways
Abbott's Q4 2019 sales increased by 7.1 percent on a reported basis and 8.5 percent on an organic basis. The company is entering 2020 with good momentum and targeting continued strong growth.
Worldwide sales increased 7.1 percent on a reported basis and 8.5 percent on an organic basis.
Nutrition sales increased 5.2 percent on a reported basis and 5.8 percent on an organic basis.
Medical Devices sales increased 9.7 percent on a reported basis and 11.3 percent on an organic basis.
Established Pharmaceuticals sales increased 7.8 percent on a reported basis and 10.0 percent on an organic basis.
Abbott
Abbott
Forward Guidance
Abbott is issuing full-year 2020 guidance for organic sales growth of 7.0 to 8.0 percent and diluted earnings per share from continuing operations under GAAP of $2.35 to $2.45. Excluding specified items, projected adjusted diluted earnings per share from continuing operations would be $3.55 to $3.65 for the full year 2020.
Positive Outlook
- Full-year 2020 organic sales growth of 7.0 to 8.0 percent.
- Full-year 2020 diluted earnings per share from continuing operations under GAAP of $2.35 to $2.45.
- Projected adjusted diluted earnings per share from continuing operations would be $3.55 to $3.65 for the full year 2020.
- First-quarter 2020 diluted earnings per share from continuing operations under GAAP of $0.40 to $0.42.
- Projected adjusted diluted earnings per share from continuing operations would be $0.69 to $0.71 for the first quarter.